NRx Pharmaceuticals secures FDA approval for NRX-101 expanded access
NRx Pharmaceuticals announced FDA approval for an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, to augment accelerated TMS for Treatment-Resistant Depression. The protocol enables compassionate access for patients who cannot enter the pivotal SPARC-TMS trial, with the company covering drug costs initially. NRx emphasized the stability and GMP manufacturing of NRX-101 compared to compounded DCS alternatives.
*this image is generated using AI for illustrative purposes only.
NRx Pharmaceuticals announced the approval by the FDA of an Intermediate Population Expanded Access Protocol for the use of NRX-101, a fixed dose combination of D-cycloserine (DCS) and lurasidone for the augmentation of accelerated Transcranial Magnetic Stimulation (TMS). This protocol is designed to make NRX-101 available under FDA-authorized compassionate care mechanisms for patients with serious or life-threatening medical conditions, specifically those with Treatment-Resistant Depression who cannot access the pivotal trial.
The company is developing NRX-101 to enhance the effectiveness of TMS in treating Treatment Resistant Depression and Suicidality. DCS has been demonstrated to have potent neuroplastic effects, which is believed to be key to the reversal of depression and suicidality. NRx Pharmaceuticals has initiated a pivotal clinical trial, the Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) study, to assess the effect of NRX-101 in augmenting TMS to achieve remission from Depression and Suicidality. This study will be conducted in both civilian and military treatment facilities.
Key Details of the Expanded Access Protocol
| Aspect | Detail |
|---|---|
| Drug Name | NRX-101 |
| Composition | Fixed dose combination of D-cycloserine (DCS) and lurasidone |
| Purpose | Augmentation of accelerated Transcranial Magnetic Stimulation (TMS) |
| Target Condition | Treatment-Resistant Depression and Suicidality |
| Regulatory Mechanism | FDA-authorized compassionate care mechanisms |
Physicians who wish to provide NRX-101 in association with accelerated TMS for patients with Treatment-Resistant Depression may register at the company's dedicated portal. Initially, the company will be charging only for shipping and FDA-required data collection costs, but not for the investigational drug.
Manufacturing and Safety Considerations
The doses of DCS required for neuroplastic effects are below the dose currently marketed for tuberculosis, leading to increased use of compounded versions. However, compounded drugs are neither supervised nor approved by the US FDA. NRx Pharmaceuticals noted that DCS is highly susceptible to degradation without special formulation processes, requiring two years of research and development to properly control impurities and achieve long-term stability for NRX-101. By making NRX-101 available under the Expanded Access Protocol, the company aims to assure that patients receive a regulated and GMP-manufactured version of the drug while pivotal clinical trials are underway.
"We at NRx deeply appreciate the engagement of the FDA Division of Psychiatry Products and their support of expanded access to regulated and GMP-manufactured D-cycloserine to enhance TMS effectiveness," said Prof. Joshua Brown, MD, PhD, the Company’s Chief Medical Innovation Officer.
What are the anticipated timelines for the SPARC-TMS pivotal trial to report initial efficacy results?
How will the company manage the transition from compassionate use pricing to commercial pricing if the drug gains full approval?
What strategies will NRx employ to differentiate NRX-101 from existing compounded D-cycloserine products in the market?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
